Clinical trial
A Phase 1/1b, Open-label Study of Pevonedistat (MLN4924, TAK-924) as Single Agent and in Combination With Azacitidine in Adult East Asian Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
NCT02782468 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/1b, Open-label Study of Pevonedistat (MLN4924, TAK-924) as Single Agent and in Combination With Azacitidine in Adult East Asian Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 16, 2016
- Completion date
- January 25, 2022
- Enrollment
- 23 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.